C3 Pharmaceuticals, a cannabinoid-focused biopharmaceutical company, has secured $99.3 million in funding to expand its manufacturing operations and introduce its cannabis-based tablet, Idrasil, to the U.S. and international markets. The company is also facing legal challenges related to Idrasil, with the SEC pursuing a lawsuit against its co-founders.